WO2013043013A3 - Ｅｂｖ 감염 ｂ 세포 유래의 복합 사이토카인을 포함하는 수지상세포 성숙 유도용 조성물 - Google Patents

Ｅｂｖ 감염 ｂ 세포 유래의 복합 사이토카인을 포함하는 수지상세포 성숙 유도용 조성물 Download PDF

Info

Publication number
WO2013043013A3
WO2013043013A3 PCT/KR2012/007660 KR2012007660W WO2013043013A3 WO 2013043013 A3 WO2013043013 A3 WO 2013043013A3 KR 2012007660 W KR2012007660 W KR 2012007660W WO 2013043013 A3 WO2013043013 A3 WO 2013043013A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
ebv
maturation
infected
inducing
Prior art date
Application number
PCT/KR2012/007660
Other languages
English (en)
French (fr)
Other versions
WO2013043013A2 (ko
Inventor
허대영
박가빈
김영석
송현근
이현경
Original Assignee
인제대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인제대학교 산학협력단 filed Critical 인제대학교 산학협력단
Publication of WO2013043013A2 publication Critical patent/WO2013043013A2/ko
Publication of WO2013043013A3 publication Critical patent/WO2013043013A3/ko
Priority to US14/220,138 priority Critical patent/US9845456B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 EBV 감염 B 세포에서 발현이 유도된 CD150의 자극을 통해 생성되는 복합 사이토카인을 포함하는 수지상세포 성숙 유도용 조성물에 관한 것이다. 본 발명에 따르면, 기존에 7일 가량 걸렸던 수지상세포의 성숙 과정을 2일로 단축시킬 수 있어, 보다 경제적이고 효과적으로 수지상세포를 제조할 수 있다.
PCT/KR2012/007660 2011-09-23 2012-09-24 Ｅｂｖ 감염 ｂ 세포 유래의 복합 사이토카인을 포함하는 수지상세포 성숙 유도용 조성물 WO2013043013A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/220,138 US9845456B2 (en) 2011-09-23 2014-03-20 Composition containing complex cytokines derived from EBV-infected B cells for inducing the maturation of dendritic cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110096312A KR101294528B1 (ko) 2011-09-23 2011-09-23 Ｅｂｖ 감염 ｂ 세포 유래의 복합 사이토카인을 포함하는 수지상세포 성숙 유도용 조성물
KR10-2011-0096312 2011-09-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/220,138 Continuation US9845456B2 (en) 2011-09-23 2014-03-20 Composition containing complex cytokines derived from EBV-infected B cells for inducing the maturation of dendritic cells

Publications (2)

Publication Number Publication Date
WO2013043013A2 WO2013043013A2 (ko) 2013-03-28
WO2013043013A3 true WO2013043013A3 (ko) 2013-08-01

Family

ID=47915044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007660 WO2013043013A2 (ko) 2011-09-23 2012-09-24 Ｅｂｖ 감염 ｂ 세포 유래의 복합 사이토카인을 포함하는 수지상세포 성숙 유도용 조성물

Country Status (3)

Country Link
US (1) US9845456B2 (ko)
KR (1) KR101294528B1 (ko)
WO (1) WO2013043013A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9921327B2 (en) 2015-03-25 2018-03-20 Cgg Services Sas Submerged front end buoy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100109099A (ko) * 2009-03-31 2010-10-08 주식회사 중외제약 암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법,이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2696751B1 (fr) 1992-10-09 1994-12-09 Cray Valley Sa Compositions de résines chargées moulables en feuilles aptes à être transformées par compression et leur application à la production de pièces moulées.
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
DE69840739D1 (de) 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100109099A (ko) * 2009-03-31 2010-10-08 주식회사 중외제약 암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법,이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FERRAND, V. ET AL.: "Absence of SLAM mutations in EBV-associated lymphoproliferative disease patients.", J. MED. VIROL., vol. 70, no. 1, May 2003 (2003-05-01), pages 131 - 136 *
MIYAUCHI, K. ET AL.: "Cytokine signatures of transformed B cells with distinct Epstein- Barr virus latencies as a potential diagnostic tool for B cell lymphoma.", CANCER SCI., vol. 102, no. 6, June 2011 (2011-06-01), pages 1236 - 1241 *
MURABAYASHI, N. ET AL.: "Susceptibility of human dendritic cells (DCs) to measles virus (MV) depends on their activation stages in conjunction with the level of CDw 150: role of Toll stimulators in DC maturation and MV amplification.", MICROBES INFECT., vol. 4, no. 8, July 2002 (2002-07-01), pages 785 - 794 *
YURCHENKO, M. ET AL.: "CD150-mediated Akt signalling pathway in normal and malignant B cells.", EXP. ONCOL., vol. 33, no. 1, March 2011 (2011-03-01), pages 9 - 18 *

Also Published As

Publication number Publication date
KR101294528B1 (ko) 2013-08-07
US20140242694A1 (en) 2014-08-28
KR20130032606A (ko) 2013-04-02
WO2013043013A2 (ko) 2013-03-28
US9845456B2 (en) 2017-12-19

Similar Documents

Publication Publication Date Title
JOP20210065A1 (ar) عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة
JO3306B1 (ar) تراكيب وطرق لطلاء الأظافر قابل للمعالجة بالأشعة فوق البنفسجية
MY182428A (en) Crystalline forms of a prolyl hydroxylase inhibitor
MX2019004568A (es) Produccion mejorada de derivados de acidos grasos.
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
MX2019004378A (es) Edulcorante de estevia altamente soluble.
MX369563B (es) Mejora de resistencia a la sequia en plantas: pectinasa.
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX2012002019A (es) Sistema de placa de pozos profundos con tapa.
IN2015DN03237A (ko)
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
NZ629709A (en) Compounds and methods for improving plant performance
MX2014004083A (es) Metodo para aislar ingenol.
PH12014501353A1 (en) Method for preparing cysteine or a derivative thereof using a novel o-phosphoserine sulfhydrylase
NZ709362A (en) Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine
MX2010005015A (es) Metodos para preparar capecitabina y un compuesto de carbonato trialquilo rico en beta-anomero.
MX352071B (es) Ésteres de lactato eterificados, método de producción de los mismos y uso de los mismos para intensificar el efecto de agentes protectores de plantas.
MY165744A (en) Process for the preparation of trisilylamine from monochlorosilane and ammonia
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
GB2523674A (en) Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
WO2013043013A3 (ko) Ｅｂｖ 감염 ｂ 세포 유래의 복합 사이토카인을 포함하는 수지상세포 성숙 유도용 조성물
MX337070B (es) Método para preparar un conjugado klh-egfrviii.
MX2013010001A (es) Derivados de androstanediol como compuestos reguladores del crecimiento de las plantas.
TN2013000128A1 (en) Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation
UA46588U (en) Process for the preparation of s(+)-6-aryl-(trifluoro)acetyl-6-trifluoromethyl-5-6-dihydropyridine-2(1h)-ones

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12834312

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12834312

Country of ref document: EP

Kind code of ref document: A2